Clinical trials: Malignant Melanomas
Melanoma
A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)
This is an observational, national, retrospective study consisting of pediatric patients with advanced (spread or unremoveable) melanoma identified in the DMTR in the Netherlands
- Trial name
- NCT04196452
- Testing
- Ipilimumab
- Volunteers
- 10 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
- Conditions
- Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
- Trial name
- NCT05358938
- Testing
- Exercise, Checkpoint Blockade, Immune
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Uveal Melanoma
Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma
Single arm study with dose escalation Phase Ib cohort followed by a Phase II cohort. PAC-1 (PO) will be given daily on Days 1 through 21 of each cycle (28-day cycle).
- Trial name
- NCT04589832
- Testing
- PAC-1, Entrectinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Arkadiusz Z. Dudek, MD
Melanoma (Skin), Intraocular Melanoma
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
The purpose of this study is to evaluate the safety and immunogenicity of a DNA vaccine encoding a melanosomal antigen in melanoma patients at risk for disease progression or recurrence.
- Trial name
- NCT00471133
- Testing
- Xenogeneic Tyrosinase DNA Vaccine, TriGrid Delivery System for Intramuscular Electroporation
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Ichor Medical Systems Incorporated
Melanoma
Establishment and Standardization of a Platform for In-depth Tumour Profiling (TUPRO) in Patients With Melanoma
TUPRO-Melanoma is the first project of the Tumour Profiler (TUPRO) research collaboration, which in the long-term aims to generate data that will help to understand and report the individual tumour biology and the clinical…
- Trial name
- TUPRO (NCT06463509)
- Testing
- Establishment of an in-deepth tumor profiling platform
- Where
- Switzerland
- Volunteers
- 116 people
- Sponsor
- Reinhard Dummer
Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS), Epidermal Nevus Syndrome
Burosumab for CSHS
Burosumab (also known as the drug, Crysvita®) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23), leading to an increase in serum…
- Trial name
- NCT03993821
- Testing
- Burosumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Laura Tosi
Melanoma (Skin) Stage IV, Remission
Quality of Life in Patients With Multimetastatic Melanoma Currently in Remission (QUALM)
Few studies have been conducted on the quality of life of patients with stage IV melanoma. Particularly, there is no data regarding the quality of life of patients with a multimetastatic melanoma currently in remission.
- Trial name
- QUALM (NCT03518814)
- Testing
- Questionnaires
- Where
- 2 sites in France
- Volunteers
- 40 people
- Sponsor
- Lille Catholic University
Advanced or Metastatic Solid Tumor
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence of antitumor activity of PLN-101095 in combination with pembrolizumab…
- Trial name
- NCT06270706
- Testing
- PLN-101095, Pembrolizumab
- Where
- 22 sites in United States, Spain
- Volunteers
- 124 people
- Sponsor
- Pliant Therapeutics, Inc.
Melanoma
A Study of GC101 TIL in Advanced Melanoma
98 participants will be randomly assigned 1:1 to the experimental group and the control group for the Phase II clinical trial，this trail is expected to be finished in 24 months
- Trial name
- MIZAR-003 (NCT06703398)
- Testing
- GC101 TIL, dacarbazine, temozolomide, paclitaxel ,platinum or cisplatin
- Where
- China
- Volunteers
- 98 people
- Sponsor
- Shanghai Juncell Therapeutics
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: This phase II trial is studying how well vaccine therapy works in treating patients with stage III or stage IV melanoma that cannot be…
- Trial name
- NCT00089206
- Testing
- incomplete Freund's adjuvant, multi-epitope melanoma peptide vaccine, sargramostim
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Virginia
Naevi
Development of an Aid to Melanoma Detection Using Artificial Intelligence Algorithms Based on Images From the VECTRA 3D System.
The background to this research is that frequent medical screening of the general population for melanoma is not feasible. The real challenge of this project is to develop an automatic process for detecting any potential…
- Trial name
- SELF DETECT (NCT06999499)
- Testing
- Scanner of the whole body using the VECTRA 3D
- Where
- France
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Melanoma
A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment
The primary purpose of this study is to characterize the safety, tolerability, and dose-limiting toxicities (DLTs) of relatlimab in combination with ipilimumab.
- Trial name
- NCT03978611
- Testing
- Relatlimab, Ipilimumab
- Where
- 28 sites in United States, Belgium and 4 more
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Melanoma
Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
This was a Phase 2, open-label study of the NY-ESO-1 ISCOMATRIX® (ISCOM) vaccine administered as an intramuscular injection given every 4 weeks to subjects with measurable advanced malignant melanoma.
- Trial name
- NCT00518206
- Testing
- NY-ESO-1 ISCOMATRIX® vaccine, Cyclophosphamide
- Where
- 2 sites in Australia
- Volunteers
- 46 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma, Lung Cancer
Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors
The recent approval of ICB treatments targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1/PD-L1) by the US Food and Drug Administration has offered an improved treatment chance for a variety of…
- Trial name
- NCT04860076
- Testing
- Pembrolizumab
- Where
- Belgium
- Volunteers
- 400 people
- Sponsor
- Asylia Diagnostics BV
Melanoma Stage III, Melanoma Stage IV
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
The primary objective of this Phase 1 clinical trial is to evaluate the feasibility and tolerability of a novel generation of gene-modified tumor infiltrating lymphocytes (TILs) in a cohort of 10 patients aged 18-75 diagnosed…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Melanoma
- Trial name
- ADP-TILIL7 (NCT06204991)
- Testing
- ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- Inge Marie Svane
Solid Tumor, Breast Cancer
Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients
This Phase Ib/II study is an open label, multicenter study. The study is divided in two parts: Phase I: an open-label, dose escalation study of F16IL2 in combination with paclitaxel for patients with solid tumours, bladder…
- Conditions
- Solid Tumor, Breast Cancer, Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT01134250
- Testing
- F16IL2 in combination with paclitaxel
- Where
- 5 sites in Italy
- Volunteers
- 48 people
- Sponsor
- Philogen S.p.A.
Non-Small Cell Lung Cancer, Renal Cell Carcinoma
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
The purpose of this study is to evaluate participant preference for coformulated hyaluronidase/pembrolizumab pembrolizumab (+) berahyaluronidase alfa [MK-3475A] administered subcutaneously (SC) over pembrolizumab [MK-3475]…
- Conditions
- Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
- Trial name
- NCT06099782
- Testing
- Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
- Where
- 45 sites in United States, Argentina and 8 more
- Volunteers
- 147 people
- Sponsor
- Merck Sharp & Dohme LLC
Melanoma, Stage I, Melanoma Stage III
Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors
This is a prospective, multi-centred cohort study whereby the EUNASS Study questionnaire will be administered electronically to identify needs of melanoma survivors, the extent to which these needs are being met, and identify…
- Conditions
- Melanoma, Stage I, Melanoma Stage III, Melanoma, Stage II
- Trial name
- EUNASS (NCT04675346)
- Testing
- Questionnaire
- Where
- United Kingdom
- Volunteers
- 252 people
- Sponsor
- Oxford University Hospitals NHS Trust
Melanoma
An Exploratory Tumor Biopsy-driven Study to Understand the Relationship Between Biomarkers and Clinical Response in Melanoma Patients Receiving REGN2810 (Anti-PD-1)
This study is being conducted to compare the relationship of patient response to treatment to changes in tumor environment.
- Trial name
- NCT03002376
- Testing
- REGN2810
- Where
- 8 sites in Netherlands, Serbia and 2 more
- Volunteers
- 47 people
- Sponsor
- Regeneron Pharmaceuticals
Melanoma (Skin Cancer), Artificial Intelligence (AI)
Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30).
- Conditions
- Melanoma (Skin Cancer), Artificial Intelligence (AI), Pediatric Cancer
- Trial name
- AI-MEL (NCT06621810)
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- German Cancer Research Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.